Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%

• Status: Withdrawn
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the feasibility of rapid evaluation and administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the progression or improves recovery of patients who are randomly assigned to treatment versus standard of care.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fraser Health
• Treatments: Maleic acid; Timolol

Criteria

Inclusion Criteria:

• Age >40

• Sudden, painless monocular vision loss with edema of the optic disc

• Clinical diagnosis is Non-Arteritic Anterior Ischemic Optic Neuropathy

• Relative Afferent Pupil Defect (RAPD) at first study visit

Exclusion Criteria:

• Onset of vision loss >48 hours from time of enrollment

• History of Asthma or COPD

• History of Heart Block or Sinus Bradycardia

• Allergy to any beta blocker

• History of Multiple Sclerosis or optic neuropathy

• Active Ocular Inflammation on examination

• Currently being treated for Cancer or systemic vasculitis

• History of Glaucoma or use of medications that lower IOP

• Symptomatic cataract, retinopathy, macular disease or amblyopia in the symptomatic eye

• IOP of <10 at baseline

• Ocular surgery in past three months

• Women who are pregnant, breast-feeding or may become pregnant

• Inability to provide informed consent or follow up at three months

• Currently enrolled in any other study drug trial or previously enrolled in this study